What is HC Wainwright’s Estimate for EPRX Q2 Earnings?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Research analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of Eupraxia Pharmaceuticals in a note issued to investors on Tuesday, March 17th. HC Wainwright analyst B. Folkes anticipates that the company will earn ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q4 2026 earnings at ($0.21) EPS and FY2030 earnings at $0.17 EPS.

Several other research analysts have also commented on the stock. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Cantor Fitzgerald boosted their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, January 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Finally, Lifesci Capital raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eupraxia Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Stock Up 2.6%

Shares of Eupraxia Pharmaceuticals stock opened at $7.58 on Wednesday. The business has a 50 day moving average of $8.29 and a 200 day moving average of $6.87. Eupraxia Pharmaceuticals has a 52 week low of $2.68 and a 52 week high of $9.32. The company has a market cap of $272.58 million, a PE ratio of -7.36 and a beta of 1.27.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21).

Institutional Trading of Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of EPRX. XTX Topco Ltd purchased a new position in Eupraxia Pharmaceuticals during the 4th quarter valued at about $122,000. Ikarian Capital LLC purchased a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $4,606,000. Squadron Capital Management LLC purchased a new position in shares of Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $3,775,000. SummitTX Capital L.P. bought a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth approximately $1,328,000. Finally, Quadrature Capital Ltd bought a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth approximately $326,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.